News | November 10, 2021
US govt places additional order of 1.4 million courses of molnupiravir
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Filing marks first protein-based vaccine submitted to MHRA for authorization
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
The authority also allowed mix and match of booster doses once the primary vaccine has been administered.
The Amplitude Solution gives laboratories the ability to scale Covid-19 PCR testing and process up to 8,000 samples a day
Subscribe To Our Newsletter & Stay Updated
